总部位于爱尔兰的专业制药商Mallinckrodt Plc(MNK)周二宣布，将以大约13亿美元收购Cadence制药公司(CADX)，从而获得后者的镇痛药物Ofirmev。FDA于2010年11月批准了Cadence的Ofirmev，用于退热、镇痛，该药是首个对乙酰氨基酚静脉注射剂。2012年Ofirmev的销售额为5010万美元，2013年翻番至1.1亿美元。

    Cadence是一家总部位于加州圣迭戈的生物制药公司。根据协议，Mallinckrodt将为每股Cadence股票支付14美元现金，较该股周一收盘价11.07美元溢价约27%。

　此项交易已获得双方董事会的一致批准，预计将于3月中到3月底之间完成，届时Cadence将成为Mallinckrodt的一个子公司。

Mallinckrodt adds pain drug with $1.3 billion Cadence deal

(Reuters) - Specialty pharmaceuticals company Mallinckrodt Plc said it would buy pain drug maker Cadence Pharmaceuticals Inc for about $1.3 billion to expand in the hospital market, where Cadence's products are widely used.

The deal will add Cadence's Ofirmev - an intravenous acetaminophen formulation for use in pain and fever - to Mallinckrodt's portfolio of pain products.

The drug, which was approved in November 2010, is expected to have generated sales of $110.5 million in 2013.

Ofirmev, used in more than 2,350 U.S. hospitals, has been used to treat an estimated 6-7 million patients since its launch in January 2011, the two companies said in a statement.

Mallinckrodt said on Tuesday it would pay $14 in cash per Cadence share, representing a premium of about 27 percent to Cadence's Monday close.

Cadence shares were trading slightly above the offer price at $14.03 before the bell, while Mallinckrodt was up 8 percent.

"Ofirmev's growth is driven by an expanding base of physicians who are prescribing the product for an increasing number of surgical patients," Mallinckrodt CEO Mark Trudeau said in a statement.

"The product will be an outstanding addition to the brands component of Mallinckrodt's specialty pharmaceutical segment."

Dublin-based Mallinckrodt, spun off from Covidien Plc last July, makes drugs for pain management, cerebral or spinal spasticity, inflammatory diseases and depression. It also makes generic drugs and active pharmaceutical ingredients.

Mallinckrodt said it received debt financing commitments from affiliates of Deutsche Bank Securities. The commitments, along with cash on hand, are expected to fund the deal, it said.

Mallinckrodt was advised by Deutsche Bank Securities and its legal advisers were Wachtell, Lipton, Rosen & Katz in the United States and Arthur Cox in Ireland.

San Diego, California-based Cadence was advised by Lazard and Centerview Partners, and its legal advisor was Latham & Watkins LLP.

(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)

关键词： Mallinckrodt 收购 Cadence 镇痛药 Ofirmev

免责声明： 

      本文仅供专业人士学术交流探讨，不作为诊疗及用药依据。 

      如有侵权，请联系我们删除